MRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice.

ABSTRACT: In vivo delivery of antigen-encoding mRNA is a promising approach to personalized cancer treatment. The therapeutic efficacy of mRNA vaccines is contingent on safe and efficient gene delivery, biological stability of the mRNA, and the immunological properties of the vaccine. Here we describe the development and evaluation of a versatile and highly efficient mRNA vaccine-delivery system that employs charge-altering releasable transporters (CARTs) to deliver antigen-coding mRNA to antigen-presenting cells (APCs). We demonstrate in human peripheral blood mononuclear cells that CART vaccines can activate a robust antigen-specific immune response against mRNA-encoded viral epitopes. In an established mouse model, we demonstrate that CARTs preferentially target professional APCs in secondary lym

SUBMITTER: Haabeth OAW 

PROVIDER: S-EPMC6166849 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature